Urinary fatty acid-binding protein 1: an early predictive biomarker of kidney injury

In the development of novel therapeutic strategies for kidney disease, new renal biomarkers for early detection and accurate evaluation of renal injury are urgently required for both acute kidney injury (AKI) and chronic kidney disease (CKD). Fatty acid-binding protein 1 (FABP1) is expressed in renal proximal tubule cells and shed into urine in response to hypoxia caused by decreased peritubular capillary blood flow. To clarify the role of urinary FABP1 in kidney disease, we established human FABP1 transgenic mice and evaluated the responses of FABP1 to several AKI and CKD models. Moreover, there are accumulating clinical data that urinary FABP1 can detect human AKI earlier than serum creatinine and can distinguish the risk population for AKI. Investigation with “humanized” FABP1 transgenic mice and measurement of clinical samples allowed us to develop urinary FABP1 as a new renal biomarker. Further clinical studies are necessary to confirm the potential of urinary FABP1 for clinical application.

Download Full-text

Urinary liver-type fatty acid-binding protein level as a predictive biomarker of contrast-induced acute kidney injury

European Journal of Clinical Investigation ◽

10.1111/j.1365-2362.2011.02620.x ◽

2011 ◽

Vol 42 (5) ◽

pp. 557-563 ◽

Cited By ~ 37

Author(s):

Kenichi Manabe ◽

Hiroshi Kamihata ◽

Masayuki Motohiro ◽

Takeshi Senoo ◽

Susumu Yoshida ◽

...

Keyword(s):

Acute Kidney Injury ◽

Fatty Acid ◽

Protein Level ◽

Fatty Acid Binding Protein ◽

Binding Protein ◽

Kidney Injury ◽

Predictive Biomarker ◽

Fatty Acid Binding ◽

Acid Binding Protein

Download Full-text

Roles of human liver type fatty acid binding protein in kidney disease clarified using hL-FABP chromosomal transgenic mice

Nephrology ◽

10.1111/j.1440-1797.2011.01469.x ◽

2011 ◽

Vol 16 (6) ◽

pp. 539-544 ◽

Cited By ~ 26

Author(s):

ATSUKO KAMIJO-IKEMORI ◽

TAKESHI SUGAYA ◽

KATSUOMI MATSUI ◽

TAKESHI YOKOYAMA ◽

KENJIRO KIMURA

Keyword(s):

Fatty Acid ◽

Kidney Disease ◽

Transgenic Mice ◽

Human Liver ◽

Fatty Acid Binding Protein ◽

Binding Protein ◽

Fatty Acid Binding ◽

Acid Binding Protein

Download Full-text

Faculty Opinions recommendation of Performance of urinary liver-type fatty acid-binding protein in acute kidney injury: a meta-analysis.

Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature ◽

10.3410/f.717969472.793470220 ◽

2013 ◽

Author(s):

Zoltan Huba Endre

Keyword(s):

Acute Kidney Injury ◽

Fatty Acid ◽

Fatty Acid Binding Protein ◽

Binding Protein ◽

Meta Analysis ◽

Kidney Injury ◽

Fatty Acid Binding ◽

Acid Binding Protein

Download Full-text

Clinical utility of urinary liver-type fatty acid binding protein measured by latex-enhanced turbidimetric immunoassay in chronic kidney disease

Clinical Chemistry and Laboratory Medicine (CCLM) ◽

10.1515/cclm-2015-1084 ◽

2016 ◽

Vol 54 (10) ◽

Cited By ~ 3

Author(s):

Atsuko Kamijo-Ikemori ◽

Takeshi Sugaya ◽

Maki Yoshida ◽

Seiko Hoshino ◽

Satoshi Akatsu ◽

...

Keyword(s):

Chronic Kidney Disease ◽

Fatty Acid ◽

Kidney Disease ◽

Clinical Utility ◽

Fatty Acid Binding Protein ◽

Binding Protein ◽

Assay Method ◽

Enzyme Linked Immunosorbent Assay ◽

Fatty Acid Binding ◽

Acid Binding Protein

AbstractBackground:Urinary liver-type fatty acid binding protein (L-FABP) measured by enzyme-linked immunosorbent assay method (ELISA) was approved as a clinical biomarker of tubular damage by the Japanese Ministry of Health, Labor and Welfare (MHLW) in 2011. We evaluated a new latex-enhanced immunoturbidimetric assay (LTIA) to evaluate the clinical utility of urinary L-FABP measured by LTIA versus an ELISA assay.Methods:LTIA with anti-human L-FABP mouse monoclonal antibodies was performed using an automated clinical chemistry analyzer. Five positive samples with low, medium and high L-FABP concentrations were analyzed to determine the within-run precision. In patients with chronic kidney disease (CKD) (n=91), urinary L-FABP levels were measured by ELISA and LTIA.Results:Measurement of urinary L-FABP revealed urinary L-FABP levels within 30 min. The within-run coefficient of variation was 10.0% for 1.4 ng/mL, 4.4% for 2.5 ng/mL, 3.2% for 9.8 ng/mL, 1.5% for 50.1 ng/mL, and 1.2% for 102.7 ng/mL. Concentrations of urinary L-FABP measured by LTIA were significantly correlated with those measured by ELISA (ρ=0.932). Proportional systematic error was almost within limits of agreement (LOA). Urinary L-FABP levels measured by LTIA were significantly correlated with urinary albumin (ρ=0.634), urinary NAG (ρ=0.688) and eGFR (ρ=–0.561).Conclusions:Measurement of urinary L-FABP by LITA was simple, speedy, and similar in quality to ELISA results. Therefore, this method was approved as external body diagnosing medicines by the Japanese MHLW in 2014. Urinary L-FABP is expected to be widely used in various pathophysiological conditions by measuring urinary L-FABP using LTIA.

Download Full-text